GlaxoSmithKline to invest £500m in Britain

British Government's recent announcement to hack Corporation Tax on income to 10 per cent has encouraged GlaxoSmithKline Plc to increase investment in Britain.

British drug-maker GlaxoSmithKline said it might spend £500 million on building a new factory to make biotech drugs and on the expansion of an existing plant in Ware, Hertfordshire.

The Government's patent box scheme announced by Chancellor Alistair Darling in the Pre-Budget report, will take effect from 2013.


GlaxoSmithKline to sell Lucozade in China

Drug multinational GlaxoSmithKline said it would sell, Lucozade, the energy drink, in the Chinese supermarkets, a move signifying drug-maker's effort to push itself into the emerging markets of the world.

GlaxoSmithKline has penned a deal with President Trading to distribute it through out China.

Lucozade was first invented by a Newcastle chemist in 1927 to provide ailing children a glucose boost.

Lucozade, which is mainly sold in Britain, Hong Kong and Ireland, generates around 400 million pounds in sales annually.


European Medicines Agency approves GlaxoSmithKline’s swine flu vaccine, Pandemrix

European Medicines Agency has given the green signal to one of UK's swine flu vaccines - the GlaxoSmithKline vaccine, called Pandemrix. The European drugs regulator's recommendation of Pandemrix implies that the vaccine can be used in the European Union within a few weeks, once the licensing formalities are completed.



Subscribe to RSS - GlaxoSmithKline